Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in non-5q- low and INT-1 risk MDS
NCT00699842Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2008
- Primary completion
- Jan 2011
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00699842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00699842.